keyword
https://read.qxmd.com/read/38652192/bortezomib-suppresses-acute-myelogenous-leukaemia-stem-like-kg-1a-cells-via-nf-%C3%AE%C2%BAb-inhibition-and-the-induction-of-oxidative-stress
#1
JOURNAL ARTICLE
Rafaela G A Costa, Maiara de S Oliveira, Ana Carolina B da C Rodrigues, Suellen L R Silva, Ingrid R S B Dias, Milena B P Soares, Ludmila de Faro Valverde, Clarissa Araujo Gurgel Rocha, Rosane Borges Dias, Daniel P Bezerra
Acute myelogenous leukaemia (AML) originates and is maintained by leukaemic stem cells (LSCs) that are inherently resistant to antiproliferative therapies, indicating that a critical strategy for overcoming chemoresistance in AML therapy is to eradicate LSCs. In this work, we investigated the anti-AML activity of bortezomib (BTZ), emphasizing its anti-LSC potential, using KG-1a cells, an AML cell line with stem-like properties. BTZ presented potent cytotoxicity to both solid and haematological malignancy cells and reduced the stem-like features of KG-1a cells, as observed by the reduction in CD34- and CD123-positive cells...
April 2024: Journal of Cellular and Molecular Medicine
https://read.qxmd.com/read/38652054/car-t-therapy-followed-by-hematopoietic-stem-cell-transplantation-can-improve-survival-in-children-relapsed-refractory-philadelphia-chromosome-positive-b-cell-acute-lymphoblastic-leukemia
#2
JOURNAL ARTICLE
Yao Li, Guan-Hua Hu, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Pan Suo, Yu Wang, Yi-Fei Cheng, Xiao-Jun Huang
BACKGROUND: Philadelphia chromosome (Ph)-positive B-cell acute lymphoblastic leukemia (ALL) has a high complete remission (CR) rate, but relapse and prolonged measurable residual disease remain serious problems. We sought to describe the CR rate measurable residual disease negative rate and address the results and safety of pediatric patients who underwent after receiving chimeric antigen receptor (CAR) specific for CD19 (CAR-19) followed by hematopoietic stem cell transplantation (HSCT) for the treatment of Ph-positive ALL...
April 23, 2024: Journal of Pediatric Hematology/oncology
https://read.qxmd.com/read/38651850/mycosis-fungoides-with-large-cell-transformation-cd30-and-b-cell-chronic-lymphocytic-leukemia
#3
JOURNAL ARTICLE
Mikela Petković, Ivana Ilić, Ružica Jurakić Tončić, Ivo Radman-Livaja, Romana Čeović
Mycosis fugnoides (MF) is an indolent cutaneous T-cell lymphoma (CTLC) and is the most common of all cutaneous lymphomas. An increased risk for developing a second primary malignancy in patients with CTCL has been described in several studies, with a range from 1.04 to 2.4 (1-4). Caucasian males are at higher risk for MF development. MF is often diagnosed at ages between 55 and 67 years, and second malignancy usually occurs 5 or 6 years after the diagnosis of MF was established (5). The most common second primary malignancies include non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), lung carcinoma, bladder carcinoma, and melanoma...
December 2023: Acta Dermatovenerologica Croatica: ADC
https://read.qxmd.com/read/38650628/identification-of-hub-genes-and-potential-molecular-mechanisms-related-to-drug-sensitivity-in-acute-myeloid-leukemia-based-on-machine-learning
#4
JOURNAL ARTICLE
Boyu Zhang, Haiyan Liu, Fengxia Wu, Yuhong Ding, Jiarun Wu, Lu Lu, Akhilesh K Bajpai, Mengmeng Sang, Xinfeng Wang
Background: Acute myeloid leukemia (AML) is the most common form of leukemia among adults and is characterized by uncontrolled proliferation and clonal expansion of hematopoietic cells. There has been a significant improvement in the treatment of younger patients, however, prognosis in the elderly AML patients remains poor. Methods: We used computational methods and machine learning (ML) techniques to identify and explore the differential high-risk genes (DHRGs) in AML. The DHRGs were explored through multiple in silico approaches including genomic and functional analysis, survival analysis, immune infiltration, miRNA co-expression and stemness features analyses to reveal their prognostic importance in AML...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38650415/-testicular-involvement-in-pediatric-lymphoid-tumors-a-review-of-the-literature-and-a-series-of-clinical-observation
#5
JOURNAL ARTICLE
S Korneeva M, A Batmanova N, R Panferova T, T Valiev T
Lymphoid tumors with testicular involvement in childhood are rare and heterogeneous. The disease may manifest with uni- or bilateral scrotal enlargement. Comprehensive examination includes evaluation of all lymph nodes involvement, as well as ultrasound examination, magnetic resonance imaging and positron emission tomography. A diagnosis is made on basis of morphological and immunohistochemical verification. Determination of lymphoid tumor variant and stage, is recommended to perform chemotherapy according to prognostic risk group, and, in some cases, transplantation of hematopoietic stem cells is required as consolidation therapy...
March 2024: Urologii︠a︡
https://read.qxmd.com/read/38649187/porphyrin-overdrive-rewires-cancer-cell-metabolism
#6
JOURNAL ARTICLE
Swamy R Adapa, Gregory A Hunter, Narmin E Amin, Christopher Marinescu, Andrew Borsky, Elizabeth M Sagatys, Said M Sebti, Gary W Reuther, Gloria C Ferreira, Rays Hy Jiang
All cancer cells reprogram metabolism to support aberrant growth. Here, we report that cancer cells employ and depend on imbalanced and dynamic heme metabolic pathways, to accumulate heme intermediates, that is, porphyrins. We coined this essential metabolic rewiring "porphyrin overdrive" and determined that it is cancer-essential and cancer-specific. Among the major drivers are genes encoding mid-step enzymes governing the production of heme intermediates. CRISPR/Cas9 editing to engineer leukemia cell lines with impaired heme biosynthetic steps confirmed our whole-genome data analyses that porphyrin overdrive is linked to oncogenic states and cellular differentiation...
July 2024: Life Science Alliance
https://read.qxmd.com/read/38648898/treosulfan-versus-busulfan-based-conditioning-in-allogeneic-hematopoietic-cell-transplantation-for-myelodysplastic-syndrome-a-single-center-retrospective-propensity-score-matched-cohort-study
#7
JOURNAL ARTICLE
Ivan Pasic, Tommy Alfaro Moya, Mats Remberger, Carol Chen, Armin Gerbitz, Dennis Dong Hwan Kim, Rajat Kumar, Wilson Lam, Arjun Datt Law, Jeffrey H Lipton, Fotios V Michelis, Igor Novitzky-Basso, Auro Viswabandya, Jonas Mattsson
Treosulfan has shown promise in allogeneic hematopoietic cell transplantation (HCT) for its myeloablative properties and low toxicity. In this single-center retrospective propensity score-matched cohort study we compared treosulfan- and busulfan-based conditioning in allogeneic HCT for patients with myelodysplastic syndrome (MDS). This study included 138 adults who underwent allogeneic HCT for MDS or chronic myelomonocytic leukemia (CMML) at Princess Margaret Hospital, Toronto 2015-2022. Using propensity score matching, we compared transplant outcomes between two well-matched cohorts who received conditioning with either fludarabine-treosulfan (FT) (n=46) or fludarabine-busulfan with total body irradiation (FBT200) (n=92)...
April 20, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38647535/convergent-epigenetic-evolution-drives-relapse-in-acute-myeloid-leukemia
#8
JOURNAL ARTICLE
Kevin Nuno, Armon Azizi, Thomas Koehnke, Caleb Lareau, Asiri Ediriwickrema, M Ryan Corces, Ansuman T Satpathy, Ravindra Majeti
Relapse of acute myeloid leukemia (AML) is highly aggressive and often treatment refractory. We analyzed previously published AML relapse cohorts and found that 40% of relapses occur without changes in driver mutations, suggesting that non-genetic mechanisms drive relapse in a large proportion of cases. We therefore characterized epigenetic patterns of AML relapse using 26 matched diagnosis-relapse samples with ATAC-seq. This analysis identified a relapse-specific chromatin accessibility signature for mutationally stable AML, suggesting that AML undergoes epigenetic evolution at relapse independent of mutational changes...
April 22, 2024: ELife
https://read.qxmd.com/read/38647418/therapeutic-efficacy-of-ras-inhibitor-trametinib-using-a-juvenile-myelomonocytic-leukemia-patient-derived-xenograft-model
#9
JOURNAL ARTICLE
Alex Q Lee, Hiroaki Konishi, Masami Ijiri, Yueju Li, Arun Panigrahi, Jeremy Chien, Noriko Satake
Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric leukemia with few effective treatments and poor outcomes even after stem cell transplantation, the only current curative treatment. We developed a JMML patient-derived xenograft (PDX) mouse model and demonstrated the in vivo therapeutic efficacy and confirmed the target of trametinib, a RAS-RAF-MEK-ERK pathway inhibitor, in this model. A PDX model was created through transplantation of patient JMML cells into mice, up to the second generation, and successful engraftment was confirmed using flow cytometry...
April 22, 2024: Pediatric Hematology and Oncology
https://read.qxmd.com/read/38645858/-latest-findings-on-the-role-of-runx1-in-bone-development-and-disorders
#10
JOURNAL ARTICLE
Zijian Pan, Xue'er Zhou, Zhiwei Cao, Jian Pan
Runt-related transcription factor (RUNX1) is a transcription factor closely involved in hematopoiesis. RUNX 1 gene mutation plays an essential pathogenic role in the initiation and development of hematological tumors, especially in acute myeloid leukemia. Recent studies have shown that RUNX1 is also involved in the regulation of bone development and the pathological progression of bone-related diseases. RUNX1 promotes the differentiation of mesenchymal stem cells into chondrocytes and osteoblasts and modulates the maturation and extracellular matrix formation of chondrocytes...
March 20, 2024: Sichuan da Xue Xue Bao. Yi Xue Ban, Journal of Sichuan University. Medical Science Edition
https://read.qxmd.com/read/38645784/recent-advancements-in-hematopoietic-stem-cell-transplantation-in-taiwan
#11
REVIEW
Chi-Cheng Li, Xavier Cheng-Hong Tsai, Wei-Han Huang, Tso-Fu Wang
Hematopoietic stem cell transplantation (HSCT) can cure malignant and nonmalignant hematological disorders. From 1983 to 2022, Taiwan performed more than 10,000 HSCT transplants. The Taiwan Blood and Marrow Transplantation Registry collects clinical information to gather everyone's experience and promote the advances of HSCT in Taiwan to gather everyone's experience and promote advances of HSCT in Taiwan. Compared with matched sibling donors, transplants from matched unrelated donors exhibited a trend of superior survival...
2024: Tzu chi medical journal
https://read.qxmd.com/read/38644693/chronic-neutrophilic-leukemia-and-atypical-chronic-myeloid-leukemia-2024-update-on-diagnosis-genetics-risk-stratification-and-management
#12
REVIEW
Natasha Szuber, Attilio Orazi, Ayalew Tefferi
Chronic neutrophilic leukemia (CNL) is a rare BCR::ABL1-negative myeloproliferative neoplasm (MPN) defined by persistent mature neutrophilic leukocytosis and bone marrow granulocyte hyperplasia. Atypical chronic myeloid leukemia (aCML) (myelodysplastic "[MDS]/MPN with neutrophilia" per World Health Organization [WHO]) is a MDS/MPN overlap disorder featuring dysplastic neutrophilia and circulating myeloid precursors. Both manifest with frequent hepatosplenomegaly and less commonly, bleeding, with high rates of leukemic transformation and death...
April 21, 2024: American Journal of Hematology
https://read.qxmd.com/read/38644613/car-t-from-cord-blood-in-a-patient-with-ph-acute-lymphoblastic-leukemia-relapsing-after-hematopoietic-stem-cell-transplantation
#13
John Donald Marra, Eugenio Galli, Sabrina Giammarco, Elisabetta Metafuni, Gessica Minnella, Federica Fosso, Sara Marietti, Simona Sica, Federica Sorà, Patrizia Chiusolo
While there is intense interest in the production of allogeneic CAR-T cells from umbilical cord units, little is known about the reactivity and persistence of CAR-T cells of umbilical origin. We report the case of a patient at our hematological center with multiple relapsing Ph+ B-ALL, notably a Blinatunomab non-responder, who underwent therapy with Brexucabtagene Autoleucel following relapse on Ponatinib post-allogeneic hematopoietic stem cell transplantation. The patient achieved a rapid CAR-T expansion and durable remission presenting in good clinical conditions 6 months post-CAR-T infusion, without manifestations of graft-versus-host disease...
April 21, 2024: European Journal of Haematology
https://read.qxmd.com/read/38644612/extramedullary-infiltration-in-pediatric-acute-myeloid-leukemia-results-from-the-therapeutically-applicable-research-to-generate-effective-treatments-target-initiative
#14
JOURNAL ARTICLE
Weiya Li, Mingyue Shi, Pan Zhou, Ying Liu, Xiaobo Liu, Xingjun Xiao, Suqiong Zuo, Yanliang Bai, Kai Sun
BACKGROUND: The outcome of extramedullary infiltration (EMI) in pediatric acute myeloid leukemia (AML) is controversial, and little is known about the implications of stem cell transplantation (SCT) and gemtuzumab ozogamicin (GO) treatment on patients with EMI. METHODS: We retrieved the clinical data of 713 pediatric patients with AML from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) dataset, and analyzed the clinical and prognostic characteristics of patients with EMI at diagnosis and relapse...
April 21, 2024: Pediatric Blood & Cancer
https://read.qxmd.com/read/38644499/graft-failure-after-allogeneic-hematopoietic-stem-cell-transplantation-in-pediatric-patients-with-acute-leukemia-autologous-reconstitution-or-second-transplant
#15
REVIEW
Tahereh Rostami, Mohammad Reza Rostami, Amir Hossein Mirhosseini, Saeed Mohammadi, Mohsen Nikbakht, Hediyeh Alemi, Naghmeh Khavandgar, Soroush Rad, Ghasem Janbabai, Seied Asadollah Mousavi, Azadeh Kiumarsi, Amir Kasaeian
BACKGROUND: Graft failure (GF) is a rare but serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). Prevention of graft failure remains the most advisable approach as there is no clear recommendation for the best strategies for reversing this complication. Administration of growth factor, additional hematopoietic progenitor boost, or a salvage HSCT are current modalities recommended for the treatment of GF. Autologous recovery without evidence of disease relapse occurs rarely in patients with GF, and in the absence of autologous recovery, further salvage transplantation following a second conditioning regimen is a potential treatment option that offers the best chances of long-term disease-free survival...
April 22, 2024: Stem Cell Research & Therapy
https://read.qxmd.com/read/38643058/aml-treatment-conventional-chemotherapy-and-emerging-novel-agents
#16
REVIEW
Mark Forsberg, Marina Konopleva
Acute myeloid leukemia (AML) is driven by complex mutations and cytogenetic abnormalities with profound tumoral heterogeneity, making it challenging to treat. Ten years ago, the 5-year survival rate of patients with AML was only 29% with conventional chemotherapy and stem cell transplantation. All attempts to improve conventional therapy over the previous 40 years had failed. Now, new genomic, immunological, and molecular insights have led to a renaissance in AML therapy. Improvements to standard chemotherapy and a wave of new targeted therapies have been developed...
April 19, 2024: Trends in Pharmacological Sciences
https://read.qxmd.com/read/38642200/discovery-of-ys-1-as-a-cell-line-of-gastric-inflammatory-cancer-associated-fibroblasts
#17
JOURNAL ARTICLE
Satoe Numakura, Masahiro Kato, Hiroshi Uozaki
BACKGROUND: Inflammatory cancer-associated fibroblasts (iCAFs) was first identified by co-culture of pancreatic stellate cells and tumor organoids. The key feature of iCAFs is IL-6high /αSMAlow . We examine this phenomenon in gastric cancer using two cell lines of gastric fibroblasts (HGF and YS-1). METHODS AND RESULTS: HGF or YS-1 were co-cultured with MKN7 (a gastric adenocarcinoma cell line) in Matrigel. IL-6 protein levels in the culture supernatant were measured by ELISA...
April 20, 2024: Molecular Biology Reports
https://read.qxmd.com/read/38638675/the-malignant-transformation-potential-of-the-oncogene-styk1-nok-at-early-lymphocyte-development-in-transgenic-mice
#18
JOURNAL ARTICLE
Yin Yang, Li Liu, Haley O Tucker
B-cell Chronic Lymphocytic Leukemia (B-CLL) is a malignancy caused by the clonal expansion of mature B lymphocytes bearing a CD5+ CD19+ (B1) phenotype. However, the origin of B-CLL remains controversial. We showed previously that STYK1/NOK transgenic mice develop a CLL-like disease. Using this model system in this study, we attempt to define the stage of CLL initiation. Here, we show that the phenotype of STYK1/NOK-induced B-CLL is heterogeneous. The expanded B1 lymphocyte pool was detected within peripheral lymphoid organs and was frequently associated with the expansions of memory B cells...
July 2024: Biochemistry and Biophysics Reports
https://read.qxmd.com/read/38636716/inos-regulates-hematopoietic-stem-and-progenitor-cells-via-mitochondrial-signaling-and-is-critical-for-bone-marrow-regeneration
#19
JOURNAL ARTICLE
Supriya Sinha, Priyanka Dhankani, Milind Nahiyera, Krishna Bhan Singh, Divya Singh, Madhav Nilakanth Mugale, Sharad Sharma, Jagavelu Kumaravelu, Madhu Dikshit, Sachin Kumar
Hematopoietic stem cells (HSCs) replenish blood cells under steady state and on demand, that exhibit therapeutic potential for Bone marrow failures and leukemia. Redox signaling plays key role in immune cells and hematopoiesis. However, the role of reactive nitrogen species in hematopoiesis remains unclear and requires further investigation. We investigated the significance of inducible nitric oxide synthase/ nitric oxide (iNOS/NO) signaling in hematopoietic stem and progenitor cells (HSPCs) and hematopoiesis under steady-state and stress conditions...
April 16, 2024: Free Radical Biology & Medicine
https://read.qxmd.com/read/38633126/post-stem-cell-transplant-maintenance-in-flt3-mut-acute-myeloid-leukemia-a-retrospective-analysis-outcomes-are-improved-with-midostaurin-but-not-with-gilteritinib
#20
JOURNAL ARTICLE
Karam Ashouri, Krithika Chennapan, Anastasia Martynova, Samvel Nazaretyan, Amir Ali, Anush Aram Ginosyan, Eric Tam, Abdullah Ladha, Karrune Woan, Preet Chaudhary, Imran Siddiqi, George Yaghmour
No abstract text is available yet for this article.
April 2024: EJHaem
keyword
keyword
460
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.